Assembly Biosciences Inc (ASMB) Q3 2019 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q3 2019 10-Q quarterly report on Nov 7, 2019 for the quarter ended Sep 30, 2019.

AI summary of MD&A and risk factor updates

Collaboration revenue $4.2M, down from $4.3M YoY
R&D expense $21.8M, up from $19.1M YoY, driven by HBV-cure spending
Net loss $70.6M for nine months, operating cash use $63.5M vs $48.2M YoY
Investing cash flow $44.7M, including $166.9M marketable-security redemptions
Cash, equivalents and marketable securities expected to fund operations at least twelve months, with additional financing required thereafter

Newly changed management risk: CEO Derek A. Small resigned August 6, 2019, replaced by John G. McHutchison
Collaboration risk: Allergan’s planned acquisition by AbbVie, announced June 2019, created uncertainty around the collaboration agreement
Regulatory risk: HHS OIG proposed Anti-Kickback Statute safe-harbor modifications October 9, 2019, potentially affecting manufacturer rebates
Clinical risk: HBV and microbiome candidates remained in early development without FDA-submitted NDA or BLA applications
Financial risk: Accumulated deficit reached approximately $412.3 million at September 30, 2019, versus $341.8 million at December 31, 2018

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.